# HtrA1 Inhibits Mineral Deposition by Osteoblasts

Kristen D Hadfield, Claire Farrington Rock, Colette A Inkson, Sarah L Dallas, Laure Sudre, Gillian A Wallis, Raymond P Boot-Handford, Ann E Canfield

► To cite this version:

Kristen D Hadfield, Claire Farrington Rock, Colette A Inkson, Sarah L Dallas, Laure Sudre, et al. HtrA1 Inhibits Mineral Deposition by Osteoblasts. Journal of Biological Chemistry, 2007, 283 (9), pp.5928 - 5938. 10.1074/jbc.m709299200. hal-04880478

HAL Id: hal-04880478

https://hal.science/hal-04880478v1

Submitted on 10 Jan 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>
# HtrA1 Inhibits Mineral Deposition by Osteoblasts

## REQUIREMENT FOR THE PROTEASE AND PDZ DOMAINS*§

Received for publication, November 13, 2007 Published, JBC Papers in Press, December 22, 2007, DOI 10.1074/jbc.M709299200

Kristen D. Hadfield<sup>†,1,2</sup>, Claire Farrington Rock<sup>†</sup>,1, Colette A. Inkson<sup>‡</sup>, Sarah L. Dallas<sup>§</sup>, Laure Sudre<sup>‡</sup>, Gillian A. Wallis<sup>‡</sup>, Raymond P. Boot-Handford<sup>‡</sup>, and Ann E. Canfield<sup>¶,¶,§</sup>

From the <sup>‡</sup>Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences and <sup>¶</sup>Cardiovascular Research Group, School of Clinical and Laboratory Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester M13 9PT, United Kingdom and the <sup>§</sup>Department of Oral Biology, School of Dentistry, University of Missouri, Kansas City, Missouri 64108

HtrA1 is a secreted multidomain protein with serine protease activity. In light of increasing evidence implicating this protein in the regulation of skeletal development and pathology, we investigated the role of HtrA1 in osteoblast mineralization and identified domains essential for this activity. We demonstrate increased HtrA1 expression in differentiating 2T3 osteoblasts prior to the appearance of mineralization. HtrA1 is subsequently down-regulated in fully mineralized cultures. The functional role of HtrA1 in matrix calcification was investigated using three complementary approaches. First, we transfected a full-length HtrA1 expression plasmid into 2T3 cells and showed that overexpression of HtrA1 delayed mineralization, reduced expression of Cbfa1 and collagen type I mRNA, and prevented BMP-2-induced mineralization. Second, knocking down HtrA1 expression using short interfering RNA induced mineral deposition by 2T3 cells. Third, by expressing a series of recombinant HtrA1 proteins, we demonstrated that the protease domain and the PDZ domain are essential for the inhibitory effect of HtrA1 on osteoblast mineralization. Finally, we tested whether HtrA1 cleaves specific matrix proteins that are known to regulate osteoblast differentiation, mineralization, and/or BMP-2 activity. Full-length recombinant HtrA1 cleaved recombinant decorin, fibronectin, and matrix Gla protein. Both the protease domain and the PDZ domain were necessary for the cleavage of matrix Gla protein, whereas the PDZ domain was not required for the cleavage of decorin or fibronectin. Type I collagen was not cleaved by recombinant HtrA1. These results suggest that HtrA1 may regulate matrix calcification via the inhibition of BMP-2 signaling, modulating osteoblast gene expression, and/or via the degradation of specific matrix proteins.

Mammalian HtrA1 is a member of the family of HtrA (high temperature requirement) proteins that were originally identified in bacteria (1). These proteins are characterized by the presence of a trypsin-like serine protease domain and either one or two PDZ domains. However, in contrast to bacterial HtrA, mammalian HtrA1 is secreted, and it also contains an IGFBP<sup>4</sup>/mac25-like domain and a Kazal-type inhibitor domain at the N terminus (2, 3). Evidence is now accumulating to suggest that HtrA1 is involved in the development and progression of several pathologies. HtrA1 has been found to exhibit properties of a tumor suppressor protein, as its expression is down-regulated in many cancer cell lines (2, 4), low levels of HtrA1 are detected in cancerous tissue compared with normal tissues (4, 5), and overexpression of this protein inhibits tumor cell growth *in vivo* and *in vitro* (4, 5). HtrA1 expression is also markedly up-regulated in several diseases, including rheumatoid arthritis and osteoarthritis (3, 6–8), Alzheimer disease (9), and Duchenne muscular dystrophy (10). In addition, a single-nucleotide polymorphism in the gene encoding HtrA1 has been shown to increase susceptibility to age-related macular degeneration (11, 12). However, the mechanisms by which HtrA1 exerts its effects are still not understood.

We demonstrated previously that HtrA1 mRNA is up-regulated as vascular pericytes undergo osteogenic differentiation and deposit a mineralized matrix *in vitro* (13). Consistent with these *in vitro* data, HtrA1 is expressed at sites of skeletal development in mouse tissues *in vivo* (6, 14), and its expression appears to be down-regulated in fully calcified bone compared with osteoid or newly formed bone matrices (6). However, the potential role of HtrA1 in osteogenesis has not yet been defined.

Osteogenesis is a complex process that is regulated by growth factors and extracellular matrix proteins acting in an interdependent manner (15–17). Interestingly, HtrA1 has been shown to inhibit the activity of members of the TGF-β family of proteins (14) that are known to regulate osteogenic differentiation and mineral deposition (18–20). In addition, recombinant HtrA1 lacking the IGFBP/mac25 and Kazal-type inhibitor domains has been reported to degrade several proteins that

<footnote>* This work was supported by grants from the Arthritis Research Campaign and the Wellcome Trust (to A. E. C. and R. B. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</footnote>

<footnote>§ The on-line version of this article (available at http://www.jbc.org) contains supplemental.</footnote>

<footnote n="1">¹ Both authors contributed equally to this work.</footnote>

<footnote n="2">² Present address: Dept. of Medical Genetics, Faculty of Medical & Human Sciences, University of Manchester, Manchester M13 0JH, UK.</footnote>

<footnote n="3">³ To whom correspondence should be addressed: University of Manchester, Michael Smith Bldg., Oxford Road, Manchester, M13 9PT, UK. Tel.: 44-161-275-5066; Fax: 44-161-275-5082; E-mail: ann.canfield@manchester.ac.uk.</footnote>

<footnote n="4">⁴ The abbreviations used are: IGFBP, insulin-like growth factor-binding protein; TGF-β, transforming growth factor-β; MGP, matrix Gla protein; siRNA, short interfering RNA; nt, nucleotide; BisTris, 2-[bis(2-hydroxyethyl)-amino]-2-(hydroxymethyl)propane-1,3-diol; PBS, phosphate-buffered saline; FBS, fetal bovine serum; rHtrA1, recombinant full-length HtrA1; BMP, bone morphogenetic protein.</footnote>
have also been implicated in regulating bone formation and/or
mineralization either directly or indirectly (6, 7, 21).

The purpose of this study was to test the hypothesis that HtrA1 regulates mineral deposition in osteoblasts and to identify the domains essential for this activity. Several complementary approaches were taken. First, we determined the expression pattern of HtrA1 in differentiating 2T3 osteoblast cells, an *in vitro* model system of bone formation (22–25). Second, the effects of overexpressing and knocking down expression of HtrA1 were assessed with respect to matrix mineralization, and the response of HtrA1 overexpressing cells to BMP-2 was determined. Third, by generating recombinant full-length HtrA1 (rHtrA1) and a series of domain-specific deletion constructs, we identified which domains were essential for the inhibitory activity of HtrA1 on mineralization, and we identified potential proteolytic substrates of HtrA1. The results of these studies highlight a novel role for HtrA1 in the regulation of mineralization.

## EXPERIMENTAL PROCEDURES

*Materials*—Unless otherwise stated, all cell culture medium and growth additives were obtained from BioWhittaker. Puro-mycin hydrochloride, chondroitinase ABC, β-casein, Alizarin red S, and human plasma fibronectin were obtained from Sigma. Geneticin (G418 sulfate) was purchased from Invitrogen, and ⁴⁵Ca-labeled CaCl₂ was from GE Healthcare. Human recombinant BMP-2 was purchased from R & D Systems. Human recombinant decorin was kindly donated by Dr. Paul Bishop (Wellcome Trust Centre for Cell Matrix Research, University of Manchester) and Dr. Marian Young (NIDCR, National Institutes of Health, Bethesda). The plasmid construct pMG PcJ, containing a 398-bp fragment of the full-length mouse MGP cDNA, was a kind gift from Prof. G. Karsenty (Baylor College of Medicine, Houston, TX). Rat tail type I collagen was prepared by Alaa Aziz (Wellcome Trust Centre for Cell Matrix Research, University of Manchester).

*Antibodies*—Goat anti-HtrA1 polyclonal antibody, donkey anti-goat horseradish peroxidase-conjugated antibody, and the HtrA1 blocking peptide were from Santa Cruz Biotechnology. Anti-decorin rabbit antiserum, raised against recombinant human decorin, was donated by Dr. Paul Bishop (Wellcome Trust Centre for Cell Matrix Research, University of Manchester). Monoclonal anti-FLAG M2 antibody and monoclonal anti-β-actin antibody were obtained from Sigma. Monoclonal anti-His antibody was purchased from GE Healthcare. All secondary horseradish peroxidase-conjugated antibodies were from Dako unless otherwise stated.

*Culture and Mineralization of 2T3 Osteoblasts*—2T3 cells were a kind gift from Dr. Stephen Harris (University of Texas Health Science Center at San Antonio) and were maintained in α-minimum Eagle's medium containing 10% (v/v) FBS, 2 mM L-glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin, in a humidified incubator at 37 °C and 5% CO₂. For mineralization experiments, cells were plated on gelatin-coated dishes at a density of 1.6 × 10⁴ cells/cm² and on reaching confluency (day 3) were cultured in α-minimum Eagle's medium containing 5% FBS (v/v), 100 µg/ml L-ascorbic acid 2-phosphate (Wako, Japan), and 5 mM β-glycerophosphate. Medium

was changed every 2–3 days with or without the addition of BMP-2 (10 ng/ml). Mineral deposition was confirmed by histochemical staining with 1% (w/v) Alizarin red, pH 4.2 (26).

*Quantitation of ⁴⁵Ca Incorporation*—Mineral deposition was also quantified by measuring ⁴⁵Ca incorporation into the matrix over a period of 24 or 48 h using a method adapted from Shioi *et al.* (27). Briefly, ⁴⁵Ca (0.5 µCi/ml) was added to 2T3 cultures either 24 or 48 h prior to analysis. At each time point, medium was removed, and cells were washed twice with phosphate-buffered saline (PBS). Perchloric acid (1.3 ml/25-cm² flask) was added and the cell layer collected. To this, an equal volume of 3% (v/v) hydrogen peroxide was added, and samples were incubated at 80 °C for 1 h. Ethylene glycol (2× final volume) was mixed with cooled samples, and 1 ml of the final solution added to 10 ml of scintillation fluid (Ecoscint™ A). Samples were counted in a Beckman liquid scintillation counter. Data are expressed as the mean uptake per culture (cpm/flask) and presented as the mean ± S.E. of triplicate samples. Significant differences between control and experimental conditions were calculated using analysis of variance or *t* test as appropriate; *p* ≤ 0.05 was considered significant.

*Preparation of RNA and Real Time Quantitative PCR Analysis*—Total RNA was isolated from cultured cells using TRIzol™ reagent (Invitrogen) and incubated with turbo DNA-free DNase I (Ambion) to remove any contaminating DNA. cDNA was prepared by reverse transcription of 1 µg of DNase-treated RNA and random hexamers (Invitrogen). Reverse transcription reaction efficiency was tested by performing PCR using primers for the housekeeping gene β-actin, at 95 °C for 5 min, 57 °C for 30 s, 72 for 30 s, for 30 cycles followed by 72 °C for 4 min. Forward (F) and reverse (R) primers recognizing β-actin (GenBank™ accession number NM_007393, F, AGC CAT GTA CGT AGC CAT CC; R, CTC TCA GCT GTG GTG GTG AA), Cbfa-1 (GenBank™ accession number AF010284, F, GCA GTT CCC AAG CAT TTC AT; R, CAC TCT GGC TTT GGG AAG AG), and the α1 chain of collagen type I (GenBank™ accession number U08020, F, CAC CCT CAA GAG CCT GAG TC; R, GCT TCT TTT CCT TGG GGT TC) were designed using the primer-3 program. Real time PCR analysis was then performed for β-actin, Cbfa-1, and collagen type I in a 25-µl reaction using a pre-mixed SYBR Green PCR master mix (Applied Biosystems), 15 pmol of primer pairs, and 5 µl of cDNA and the ABI PRISM 7000 sequence detection system (Applied Biosystems). Cycling parameters were as before but for 40 cycles. The amplification efficiencies of the test genes and the reference gene, β-actin, were approximately equal as determined by serial dilution of cDNA prepared from wild-type day 3 cultures. Each sample was run in triplicate, and each sample set was analyzed twice. Amplification curves were checked for normal base-line and threshold levels during each run. A comparative method was used to determine RNA levels in which data for test genes (Δ) were normalized to levels of β-actin (CT) within each sample, and relative mRNA levels were determined using the equation 2^(Δ-CT).

*Preparation of Conditioned Medium for Protein Expression Analysis*—Cell cultures were washed 2–3 times with Hanks' balanced salt solution and incubated in serum-free medium for 1 h. Cells were then incubated in fresh serum-free medium for
## HtrA1 Inhibits Mineral Deposition

a further 24 h. The resulting conditioned medium was collected and centrifuged (5 min, 4000 × g) to remove cell debris. Supernatants were dialyzed against 50 mM ammonium bicarbonate over 72 h at 4 °C and freeze-dried. Protein samples were resuspended in 1× loading sample buffer (62.5 mM Tris/HCl, pH 6.8, 1% SDS, 5% glycerol), and total protein concentrations were determined using a BCA protein assay (Pierce), with bovine serum albumin as the standard.

*Preparation of Cell Lysates for Protein Expression Analysis*— Cultures were washed with PBS and proteins extracted using lysis buffer (20 mM Tris/HCl, pH 8.0, 150 mM NaCl, 1% (v/v) Nonidet P-40, 10% glycerol, 1 mM EDTA, 5 mM sodium fluoride, and 0.1% (v/v) SDS) containing the following protease inhibitors: leupeptin (1 µg/ml), aprotinin (1 µg/ml), pepstatin A (1 µg/ml), phenylmethylsulfonyl fluoride (1 mM), and sodium orthovanadate (1 mM) for 20 min on ice. Samples were centrifuged (5 min, 10,000 × g at 4 °C) and protein concentrations determined in the supernatants as described above.

*Generation of Full-length HtrA1 cDNA*—Total RNA was isolated from MC3T3-E1 cells using TRIzol™ reagent (Invitrogen) according to the manufacturer's protocol, and cDNA was synthesized using avian myeloblastosis virus reverse transcriptase and oligo(dT) primers. HtrA1 cDNA was generated by PCR using oligonucleotide primers designed to the full coding region of murine HtrA (GenBank™ accession number NM_019564). Expand High Fidelity Taq polymerase (Roche Applied Science) and 10% Me₂SO were used in all reactions. The full-length product was generated from three separate DNA fragments that were generated from two overlapping 5' and 3' sequences. The 5' PCR product (515 bp) was generated using the forward primer 5'-AAC GGA TCC GTC ATG CAG TCC CTG CGT A-3' and reverse 5'-AGT TGT ACT TAT GAC GCA AAC TGT T-3'. Cycling parameters used were 95 °C for 3 min followed by 30 cycles of 95 °C for 15 s, 45 °C for 30 s, and 72 °C for 45 s with a final extension at 72 °C for 4 min. The 3' PCR product (1096 bp) was generated using forward and reverse primers 5'-AGC GAC GCC AAG ACC TAC ACC AAC C-3' and 5'-AAA CGA ATT CTC CTG CCT CTG CCT AG-3'. PCR conditions used were 95 °C for 3 min followed by 35 cycles of 95 °C for 15 s, 52 °C for 30 s, and 72 °C for 2 min, with a final extension for 4 min at 72 °C. Both PCR products were ligated into pCR2.1-TOPO cloning vector (Invitrogen) and sequences confirmed using Big Dye™ terminator cycle sequencing ready reaction kit and an ABI 377 automated sequencer (Applied Biosystems Inc). These cDNA constructs were digested with HindIII (creating fragments 1–3) and through a series of ligations generated the full-length product of 1460 bp in pCR2.1. The resulting full-length HtrA1 cDNA was first ligated into pIND (Invitrogen) as an EcoRI-digested fragment (pIND-mHtrA1) and subsequently into mammalian expression vector pcDNA3.1 as a KpnI/XbaI fragment generating the pcDNA3.1-mHtrA1 expression plasmid.

*Overexpression of HtrA1 in 2T3 Osteoblasts*—2T3 cells were stably transfected with pcDNA3.1-mHtrA1 expression plasmid using the FuGENE 6 reagent (Roche Applied Science). A FuGENE 6:DNA ratio of 3:1 and 1 µg of DNA/10 cm² of cell layer was used. After 16 h, medium was replaced with fresh growth medium containing 400 µg/ml G418. Drug-resistant

colonies developed from single cells were selected either by ring cloning or by dilution cloning after 2–3 weeks. Expression of HtrA1 mRNA and protein in selected clones was determined by Western blotting of conditioned media and by Northern blotting using 15 µg total RNA and an [α-³²P]CTP-labeled HtrA1 cDNA probe. Northern blotting was performed as described (28).

*Generation of HtrA1 siRNA Expression Plasmid*—HtrA1 RNA interference effector molecules were delivered using the siRNA expression vector pSUPERIOR.neo+GFP (Oligo-Engine). The HtrA1 19-nt mRNA target sequence 5'-GGU UGA GCU GAA GAA UGG A-3' was taken from sequences provided with pre-designed siRNA 21-mer duplexes (Ambion). Preliminary experiments showed this sequence to be the most effective at knocking down the transient expression of recombinant HtrA1 in HEK293 cells. Two 60-bp oligodeoxynucleotides were designed to include the unique 19-nt sequence in both the sense and antisense direction, separated by a 9-nt spacer sequence. The sense strand of the pSuperior-HtrA1-siRNA insert is 5'-GAT CCC CGG TTG AGC TGA AGA ATG GAtcaagaATCCATCTTCAGCTCAACCTTTT-3'. The 5' end of the sense strand oligonucleotide corresponds to a BglII site and the 3' end to a thymidine termination sequence (T5) and HindIII corresponding nucleotides. The forward and reverse oligonucleotides were annealed and ligated into BglII/HindIII linearized pSUPERIOR.neo+GFP vector, downstream of the H1 promoter, according to the manufacturer's protocol. The identities of the inserted sequences were confirmed by DNA sequencing.

*Transfection of 2T3 Cells with pSUPERIOR siRNA Plasmids*— 2T3 cells were plated 24 h prior to transfection at 4 × 10⁵ cells/10-cm dish. Cells were transfected with 10 µg of the pSuperior-HtrA (pSupHtrA) and pSuperior-empty vector (pSupEV) plasmids using a calcium phosphate kit (Profection® kit, Promega). After 30 h, cells were passaged 1:2, and transfected cells were selected with 400 µg/ml G418. Neomycin-resistant cell populations were expanded, and HtrA1 expression was assessed by Western blotting of conditioned media. To confirm that knockdown of HtrA1 was specific, samples of conditioned medium and cell lysates from both cell populations were also assessed for global protein expression and for the expression of β-actin.

*Cloning and Expression of HtrA1 Recombinant Proteins*—Recombinant murine HtrA proteins were produced using a mammalian episomal expression vector (pCEP-His) and 293-EBNA cells (29). pCEP-His has been modified from the pCEP-pu/AC7 vector (30) to incorporate an N-terminal His₆ tag following a signal peptide of the BM40 protein (31). HtrA1 cDNA, without the sequence encoding for its signal peptide, was amplified from pIND/mHtrA1 using the primers 5'-GCT GAC TTG CCG TCG GGG ACC GG-3' and 5'-GTC GAC CTC CTG CCT CTG CCT AG-3'. PCR conditions were 95 °C for 3 min followed by 30 cycles of 95 °C for 15 s, 58 °C for 30 s, and 72 °C for 2 min, with a final extension for 4 min at 72 °C. A 3'-truncated HtrA1 transcript lacking the PDZ domain (HtrA1ΔPDZ) was generated using the reverse primer 5'-GTC GAC CTA CTT GGT GAC AGC TTT C-3'. Reaction times were 94 °C for 2 min followed by 25 cycles of 94 °C for 15 s, 57 °C for 30 s, and 72 °C for 1 min with a final extension for 7 min at 72 °C. The
final PCR products were cloned into pCR2.1-TOPO and
sequences confirmed. HtrA1 inserts were released by Sall
digestion and cloned into XhoI-digested pCEP-His to produce
pCEP-His/HtrA1 (H) and pCEP-His/HtrA1ΔPDZ (HΔP). Site-
directed mutagenesis (QuickChange XL site-directed mu-
tagenesis kit, Stratagene), using primers 5'-CAT CAA TTA
TGG AAA TGC CGG AGG CCC GTT AG-3' and 5'-CTA
ACG GGC CTC CGG CAT TTC CAT AAT TGA TG-3' (3)
introduced a point mutation into pCEP-His/HtrA1, which rep-
resents a mutation of the 328-serine residue to an alanine. The
resulting mutated construct pCEP-His/MutHtrA1 (MH) was
used as a template to amplify MutHtrA1ΔPDZ (MHΔP) using
the same primer pair and PCR conditions as for HtrA1ΔPDZ.
293-EBNA cells were plated 24 h prior to transfection in 10-cm
dishes at a density of 4 × 10⁵/cm² in Dulbecco's modified
Eagle's medium supplemented with 10% (v/v) FBS, 1 mM
sodium pyruvate, 50 units/ml penicillin, and 50 µg/ml strepto-
mycin. Cells were transfected with the recombinant HtrA1
expression constructs using FuGENE 6 as described above.
Cells were also transfected with pCEP-His empty vector as a
control. To select transfected cells, medium was replaced after
16 h with fresh medium containing 5 µg/ml puromycin. Cells
were maintained thereafter in medium containing 0.5 µg/ml
puromycin and 250 µg/ml G418.

Cloning and Expression of Recombinant Matrix Gla Protein—
An expression construct encoding an N-terminally FLAG
epitope-tagged mouse MGP protein (N-FLAG-MGP) was gen-
erated by PCR from the template pMGPcJ, using the forward
and reverse primers 5'-GCC CCG CTA GCT GAC TAC AAG
GAC GAC GAT GAC AAG TAC GAA TCT CAC GAA-3' and
5'-CTC GAG ACT AGT GGA TCC CAC ACT TCA GTA
A-3'. The forward primer incorporated the sequence of the
FLAG epitope (DYKDDDDK). PCR conditions were 35 cycles
of 92 °C for 45 s, 65 °C for 90 s, and 72 °C for 45 s. The 381-bp
product was ligated as an NheI/XhoI fragment into the episo-
mal expression vector pCEP-Pu/AC7 (30), and the frame of the
insert was confirmed by DNA sequencing. The pCEP-Pu-MGP
construct was transfected into 293-HEK cells as described
above for 293-EBNA cells. Transfected cells were selected and
maintained in medium containing 5 and 0.5 µg/ml puromycin,
respectively.

Preparation and Analysis of Recombinant Proteins—To gen-
erate recombinant HtrA proteins, transfected 293-EBNAs were
maintained in α-minimum Eagle's medium containing 10%
(v/v) FBS, 2 mM L-glutamine, 50 units/ml penicillin, 50 µg/ml
streptomycin, 0.5 µg/ml puromycin, and 250 µg/ml G418.
Cells were expanded into 225-cm² tissue culture flasks, and
at 90–100% confluency were prepared for conditioned
media collection as described above. After 24 h, the condi-
tioned media were centrifuged (4000 × g, 5 min) to remove
cell debris. Supernatants, containing recombinant proteins,
were concentrated ~50-fold using Amicon Ultra centrifugal
filter columns with a 10-kDa molecular mass cut-off (Milli-
pore), filtered through a 0.22-µm syringe filter, and stored at
−80 °C. Medium collected from empty vector-transfected
control cells was treated in the same manner. An aliquot (0.5
ml) of each concentrated conditioned medium was dialyzed
against 50 mM ammonium bicarbonate, freeze-dried, resus-

pended in 50 µl of 1× loading sample buffer, and the total
protein concentrations were determined using a BCA pro-
tein assay. To assay for serine protease activity, 20 µl of each
concentrated recombinant protein was incubated with 5 µg
of β-casein in 50 mM Tris/HCl, pH 8.0, at 37 °C for 2 h.
Products were separated by SDS-PAGE (12% polyacrylam-
ide) and stained with Coomassie Brilliant Blue (Sigma). The
conditioned medium from 293-EBNA cells expressing
FLAG-MGP was prepared as above and concentrated using
Amicon Ultra centrifugal columns with a 5-kDa molecular
weight cut-off.

Digestion of Matrix Proteins by Recombinant HtrA1—GAG
chains were removed from human recombinant decorin (0.2
µg) by incubation with chondroitinase ABC (0.005 units) in 0.1
M Tris/HCl, pH 8.0, 0.03 M sodium acetate at 37 °C for 16 h.
Concentrated recombinant HtrA1 proteins or empty vector
controls (20 µl) were added directly to the digested decorin and
incubated for a further 16 h at 37 °C. Samples were subjected to
SDS-PAGE (10% polyacrylamide) under reducing conditions
and protein products detected by Western blotting. Human
plasma-derived fibronectin (0.2 or 10 µg in PBS) was incubated
with HtrA1 proteins or empty vector controls (20 µl) for 16 h
at 37 °C. Products were separated by SDS-PAGE under
reducing conditions on 4–12% BisTris acrylamide gels
(Invitrogen) and either analyzed by Western blotting (0.2
µg) or by silver staining using SilverQuest™ silver staining
kit (Invitrogen). rMGP (40 µl of concentrated conditioned
medium) was incubated with HtrA1 proteins as for fibronec-
tin and products separated on 18% polyacrylamide gels and
detected by Western blotting using an anti-FLAG M2 mono-
clonal antibody. Type I collagen was prepared from rat tail
tendons and diluted to 2 mg/ml in 0.1% acetic acid. To neu-
tralize the collagen prior to analysis, 118 µl sodium bicar-
bonate was added per 1 ml of collagen (volume ratio 2:17).
Concentrated recombinant HtrA1 proteins (20 µl) were
incubated with 10 µg of type I collagen for 16 h at 37 °C.
Products were separated on 4–12% BisTris acrylamide gels
and stained with Coomassie Brilliant Blue.

Immunoblotting—Protein samples were separated by SDS-PAGE under reducing conditions and transferred to nitrocellulose membranes that were subsequently blocked overnight at 4 °C with 0.1% (v/v) Tween in PBS (PBS-T) containing 5% (w/v) milk powder or 5% (w/v) bovine serum albumin (HtrA1 blots only). All primary antibodies were incubated with membranes for 1 h at room temperature in 5% (w/v) milk powder in PBS-T (anti-decorin rabbit antiserum, 1:1000; anti-FLAG M2 monoclonal, 1:1000; anti-His monoclonal, 1:3000; and anti-β-actin monoclonal (1:4000)) or in 5% (w/v) bovine serum albumin in PBS-T (anti-HtrA1 goat polyclonal, 1:50). To confirm the specificity of the HtrA1 antibody, it was preincubated, prior to blotting, with an HtrA1 blocking peptide for 1 h at room temperature using a peptide/antibody concentration of 4:1. Incubation with appropriate secondary horseradish peroxidase-conjugated antibodies was performed for 1 h in PBS-T with 5% (w/v) dry milk (swine anti-rabbit, 1:1000; rabbit anti-mouse, 1:1000) or 5% (w/v) bovine serum albumin (donkey anti-goat, 1:1000). Membranes were washed five times for 10 min with PBS-T after each incubation, and reactivity was detected using an enhanced
## HtrA1 Inhibits Mineral Deposition

<figure><img src="image_2.png" /><figcaption>FIGURE 1. **Expression of HtrA1 in mineralizing 2T3 osteoblasts.** A, phase contrast images of 2T3 cells stained for mineralized nodule formation with Alizarin red at confluence (day 3) (panel i) and after 10 (panel ii), 13 (panel iii), and 17 (panel iv) days in culture (bar = 500 µm). Calcification is demonstrated at day 13 and 17, by positive staining with Alizarin red. B, Western blot analysis of HtrA1 expression in 2T3 cells. Serum-free conditioned media (CM), containing the secreted HtrA1 protein, was collected from 2T3 cultures at confluence and on days 10, 13, and 17. Equivalent volumes of conditioned media (CM) from each time point (1.5 ml from 5 ml total) were concentrated by freeze-drying and immunoblotted using an anti-HtrA1 polyclonal (upper panel). The blot was stripped and stained with India ink to show protein loading (lower panel).</figcaption></figure>

chemiluminescence (ECL-Plus) detection system (GE Healthcare). Samples were normalized to total protein content or to β-tubulin expression (1:500, Santa Cruz Biotechnology).

## RESULTS

**HtrA1 Is Secreted by 2T3 Osteoblasts**—Previously we reported the up-regulation of HtrA1 expression in vascular pericytes undergoing osteogenic differentiation and mineralization (13). Here we report for the first time the temporal pattern of secretion of HtrA1 protein by 2T3 osteoblasts over a 17-day culture period. Fig. 1A shows the Alizarin red staining pattern of 2T3 osteoblasts, grown to confluency (day 3, panel i) and then cultured in differentiation medium for a further 14 days (day 17). Multilayering of differentiated cells and condensed cellular areas was apparent after 10 days (Fig. 1A, panel ii). Cultures began to deposit a calcified matrix after 13 days (Fig. 1A, panel iii), which was extensively mineralized after 17 days (Fig. 1A, panel iv), as demonstrated by positive staining with Alizarin red. Serum-free conditioned media were collected from the 2T3 cultures at these time points, concentrated, and immunoblotted for HtrA1 (Fig. 1B, upper panel). HtrA1

protein was detected in 2T3 conditioned media at confluence and was markedly up-regulated in post-confluent cultures (day 10), prior to the appearance of mineralized nodules. HtrA1 was then dramatically down-regulated following the onset of mineralization (day 13). Small amounts of HtrA1 were detected in heavily mineralized cultures (day 17). Preincubation of the HtrA1 antibody with an HtrA1 immunization (blocking) peptide confirmed its specificity (data not shown). The blot was stripped and stained with India ink to show protein loading (Fig. 1B, lower panel). It is important to note that the mineralization of the 2T3 wild-type cells did not occur at exactly the same time points in every experiment. However, down-regulation of HtrA1 expression was always observed with the onset of mineralization.

**HtrA1 Overexpression Inhibits Osteoblast Mineral Deposition in Vitro**—To determine the functional role of HtrA1 in osteoblast mineralization, clones of 2T3 cells stably overexpressing HtrA1 were generated and selected for further characterization based on HtrA1 mRNA and protein expression levels, relative to wild-type controls (Fig. 2, A and B). Clone 2 (C2) consistently demonstrated the highest overexpression of HtrA1 (Fig. 2, A and B). The effect of HtrA1 overexpression on the expression of early markers of the osteogenic phenotype was examined. Real time quantitative PCR analysis revealed reduced expression of Cbfa1 and collagen type I at confluence in C2 cells compared with wild-type cells (Fig. 2, C and D). There was no difference in Cbfa1 or collagen type I mRNA expression between the wild-type cells or C2 cells on day 21 (Fig. 2, C and D). The effect of HtrA1 overexpression on mineral deposition was investigated by Alizarin red staining (Fig. 2E) and quantified by measuring $ ^{45}Ca $ incorporation into the cell layer (Fig. 2F). In these experiments, a high level of mineralization was already apparent in 2T3 wild-type cells after 10 days, which was further increased on days 13 and 17 (Fig. 2E). Markedly reduced Alizarin red staining was observed in C2 cells at time points when wild-type cells were heavily mineralized (Fig. 2E). A significant reduction in $ ^{45}Ca $ incorporation into the matrix by C2 cells compared with wild-type cells was also observed at these time points (Fig. 2F, *p* < 0.001). The data presented in Fig. 2, E and F, is representative of three separate experiments. A second clone exhibited an intermediate level of expression of HtrA1 compared with C2 and wild-type cells. In these cells, some mineralization was detected at the later time points, suggesting that the effects of HtrA1 on mineralization may be dose-dependent (see supplemental material).

**HtrA1 Overexpression Prevents BMP-2-induced Mineralization**—BMP-2 accelerates the appearance of mineralized nodules in 2T3 cells (22, 23), and HtrA1 has been demonstrated to inhibit signaling of BMP family members *in vitro* (14). Therefore, to investigate whether the overexpression of HtrA1 could suppress the effect of BMP-2 on osteoblast mineralization, wild-type cells and C2 cells were cultured in the presence of recombinant BMP-2. Treatment of wild-type cells with BMP-2 (10 ng/ml) increased the level of mineral deposition, as shown by Alizarin red staining after 13 days (Fig. 2G, panels i and iii). In contrast, mineralization was not induced by BMP-2 in C2 cells that markedly overexpress HtrA1 (Fig. 2G, panels ii and
<figure><img src="image_3.png" /><figcaption>FIGURE 2. Overexpression of HtrA1 inhibits mineralization of 2T3 osteoblasts. 2T3 osteoblasts were transfected with an HtrA1 expression plasmid, and clones were selected for further analysis. A, RNA was isolated from 2T3 wild-type (wt) cells and HtrA1 overexpressing clone C2 after 11 days in culture and analyzed for HtrA1 expression by Northern blotting. The blots were stripped and re-probed for 18 S ribosomal RNA to confirm equal loading. B, HtrA1 protein expression in wild-type cells and C2 HtrA1-overexpressing cells. Equivalent volumes of conditioned media (1 ml) from each culture were collected on day 10, concentrated, and immunoblotted using an anti-HtrA1 polyclonal. C and D, expression of Cbfa-1 (C) and collagen type I (D) mRNA in wild-type and C2 cells at day 3 (confluence) and 21 (wild-type cells mineralized, as determined by Alizarin red staining of parallel cultures) (n = 3 per variable). Data are representative of three separate experiments. E, phase contrast images of wild-type cells and C2 cells stained with Alizarin red after 10, 13, and 17 days in culture (bar = 200 µm). F, mineral deposition was quantified by measuring ⁴⁵Ca incorporation over a 48-h time period taken at days 3, 10, 13, and 17. Data are representative of three individual experiments (n = 3 in each experiment) and are presented as the mean counts ± S.E. Statistical analysis was performed using one-way analysis of variance and Tukey's post hoc test. *, p < 0.001. G, wild-type and C2 cells were cultured in mineralization-inducing medium for 13 days in the absence (panels i and ii) or presence (panels iii and iv) of BMP-2 (10 ng/ml). Alizarin red staining shows increased matrix calcification in wild-type cells treated with BMP-2 (panel iii) but no calcification in HtrA1 overexpressing C2 cells (panel iv) (bar = 500 µm).</figcaption></figure>

iv). These images are representative of four separate experiments. No mineralization was detected in the C2 cells even when BMP-2 was added at higher doses (see supplemental material).

tant for its function, a series of histidine-tagged recombinant HtrA1 proteins were expressed using 293-EBNA cells (Fig. 4A). Immunoblotting of concentrated 293-EBNA medium using a His tag reactive antibody confirmed the production

Knockdown of HtrA1 Expression Using siRNA Increases Osteoblast Mineralization—The above studies show that marked overexpression of HtrA1 inhibits matrix mineralization by osteoblasts. Therefore, complementary experiments using siRNA to knock down the expression of HtrA1 in these cells were conducted, and the effects on mineralization were determined. To enable delivery of siRNA effector molecules targeted against HtrA1 over long periods, 2T3 cells were stably transfected with the pSuperior-HtrA1 siRNA expression vector. Cells transfected with the pSuperior empty vector were used as controls. Populations of the resulting antibiotic-resistant cells (pSupHtrA1 and pSupEV) were grown to confluence (day 3) and then cultured in mineralization medium for a further 7 days (until day 10). HtrA1 expression was determined on day 4 by Western blotting of equivalent volumes of conditioned medium (Fig. 3A). Knockdown of HtrA1 expression (~90%) was confirmed in the pSupHtrA1 cells compared with the control pSupEV cells (Fig. 3A). In contrast, equivalent expression of β-actin was demonstrated in pSupEV and pSupHtrA1 cell lysates at this time point (Fig. 3B). In addition, staining of the membranes with India ink confirmed that the HtrA1 siRNA was not down-regulating protein expression *per se*. Mineralization was markedly enhanced when HtrA1 expression was knocked down compared with control cells (Fig. 3C). The data presented are representative of two separate experiments with duplicate samples.

The Protease Domain and the PDZ Domain Are Essential for the Inhibition of Osteoblast Mineralization by HtrA1—To further investigate the effects of HtrA1 on osteoblast mineralization and to determine which of the individual domains of this protein are impor-
HtrA1 Inhibits Mineral Deposition

<figure><img src="image_4.png" /></figure>

FIGURE 3. Knockdown of HtrA1 expression increases osteoblast mineralization. 2T3 osteoblasts were stably transfected with pSupHtrA1 siRNA expression vector and pSupEV control plasmid. Cultures were treated from confluence (day 3) with mineralization media for a further 7 days (day 10), and the extent of mineralization and levels of HtrA1 expression were determined. A, after 4 days in culture, conditioned medium was collected, concentrated, and 1-ml equivalents were analyzed for HtrA1 expression by Western blotting. A reduction in HtrA1 expression is evident in pSupHtrA1 cells. India ink staining of equivalent samples shows protein loading of pSupHtrA1 and pSupEV at this time point. B, Western blotting of cell lysates (10 µg) confirmed equal expression of β-actin in pSupHtrA1 and pSupEV cells. Equal protein loading was confirmed by staining of the membrane with India ink. C, phase contrast images of Alizarin red stained pSupEV (panel i) and pSupHtrA1 (panel ii) cells after 10 days in culture (bar = 200 µm).

of full-length HtrA1 (H), the serine protease mutant (MH), and the truncated forms of these proteins, which lack the PDZ domain (HΔP, MHΔP) (Fig. 4B). Both full-length HtrA1 and HtrA1ΔPDZ were confirmed to be proteolytically active as demonstrated by their abilities to degrade β-casein (Fig. 4C). Neither of the serine protease mutants (MH, MHΔP) nor medium from empty vector transfected EBNA cells degraded β-casein (Fig. 4C). Other groups have reported purification of N-terminally truncated HtrA1, which lacks the IGFBP/mac25 domain and the Kazal inhibitor domains (6, 8, 32). This truncated protein has increased protease activity when compared with the wild-type protein. Repeated attempts to purify full-length recombinant HtrA1 using nickel chromatography rendered the protease inactive, and therefore recombinant proteins were added to 2T3 cultures as concentrated 293-EBNA conditioned media. For each experiment, equal amounts of each recombinant protein (assessed by densitometric analysis of immunoblots) and equal total protein content were added to the 2T3 cultures. Conditioned media collected from empty vector transfected EBNAs were used to normalize the total protein content. Immunoblotting for HtrA1 also confirmed that the

recombinant proteins were added in at least 200-fold excess of the maximum amount produced by 2T3 cells at day 10. In the first series of experiments, 2T3 cultures were treated from confluence with empty vector, MutHtrA1, and HtrA1-conditioned media (Fig. 5, A and B). After 10 (Fig. 5A) and 13 days (not shown), Alizarin red staining showed a dramatic decrease in mineral deposition in cultures treated with HtrA1 compared with empty vector controls or cells incubated with MutHtrA1. This decrease was confirmed using the ⁴⁵Ca incorporation assay ($p < 0.001$, $n = 3$) (Fig. 5B). To further identify which domains are important for the effect of HtrA1 on matrix mineralization, 2T3 cells were then treated with empty vector, HtrA1, and HtrA1ΔPDZ-conditioned media (Fig. 5C). Cultures treated with HtrA1 showed inhibition of mineralization compared with empty vector controls; however, the truncated HtrA1 protein had no apparent effect on mineralization (Fig. 5C). Together, these results demonstrate that both the protease domain and the PDZ domain are essential for the inhibitory effect of HtrA1 on mineralization.

HtrA1 Degrades Specific Matrix-associated Proteins—The data presented in Fig. 5 demonstrated that the protease and PDZ domains were both essential for the inhibition of matrix mineralization by HtrA1. It was therefore speculated that specific matrix proteins, either associated with bone mineralization, the remodeling of the matrix prior to mineralization, or those involved in TGF-β or BMP-2 signaling were being degraded by HtrA1. To identify potential physiological substrates of HtrA1, the recombinant HtrA1 proteins were incubated with candidate proteins for 16 h at 37 °C. Among the proteins tested was fibronectin, a major noncollagenous component of mineralized bone matrix. In addition to its requirement for the assembly of matrix proteins (33–35), fibronectin has been implicated in the control of osteoblast differentiation and mineralization (36). The small leucine-rich proteoglycan decorin was chosen as it is highly expressed in bone and is known to regulate type I collagen fibril assembly (37), TGF-β activity (38, 39), and osteoblast differentiation and mineralization (40). Matrix Gla protein (MGP) was selected as it is present in cartilage, bone, and arteries (41), and the phenotype of MGP knock-out mice highlights its role in the regulation of cell differentiation and as an inhibitor of mineralization (42). Type I collagen was chosen as it is the predominant collagen in mineralized tissues and serves as a structural template for the deposition of mineral (43).

Human plasma fibronectin was cleaved by conditioned medium containing HtrA1 (H) and HtrA1ΔPDZ (HΔP), generating fragments ranging from ~200 to 150 kDa (Fig. 6A). A band at ~260 kDa (corresponding to fibronectin) was still present after incubation with the serine protease mutant MH. Immunoblotting of recombinant human decorin showed a broad band migrating between ~150 and 75 kDa (Fig. 6B, top panel, first lane). Following treatment with chondroitinase ABC, decorin migrated as a doublet of ~48 and 45 kDa, corresponding to the differently glycanated forms of the decorin core protein (Fig. 6B, middle panel, first lane). Conditioned medium containing HtrA1 (H) and HtrA1ΔPDZ (HΔP), but not the corresponding mutant proteins which
HtrA1 Inhibits Mineral Deposition

<figure><img src="image_5.png" /><figcaption>FIGURE 4. Generation of recombinant HtrA1 proteins and assessment of their proteolytic activities.
A, schematic of His-tagged recombinant HtrA1 proteins expressed using mammalian 293-EBNA cells. H, full-length HtrA1; MH, a proteolytically inactive form of HtrA1, in which the serine residue is mutated to an alanine; HΔP and MHΔP, truncated versions of H and MH in which the PDZ domain is absent. KI, Kazal-type inhibitor domain; HtrA, protease domain with proteolytic amino acid residues indicated (HDS, HDA in MH); PDZ, protein interaction domain. B, media from the 293-EBNA cells was concentrated, and Western blot analysis, using an anti-His antibody, confirmed the expression of the 50-kDa full-length MH and H and the 37-kDa truncated forms of MHΔP and HΔP. C, HtrA1 protease activity was determined by incubation of the concentrated recombinant proteins with β-casein (5 µg). Products were separated on a 12% SDS gel and stained with Coomassie Blue. EV, media from empty vector transfected EBNA-293 cells. β-Casein degradation products are evident in samples incubated with H and HΔP.</figcaption></figure>

lacked protease activity (MH, MHΔP), almost completely degraded both intact decorin and the decorin core protein (Fig. 6B). Immunoblotting with an anti-FLAG antibody against the FLAG-MGP fusion protein showed full-length recombinant MGP migrating with an approximate molecular mass of 15 kDa (Fig. 6B, lower panel, first lane). Following incubation with conditioned medium containing HtrA1, a product of ~12 kDa was detected, indicating cleavage of MGP at the C terminus. MGP was not cleaved by conditioned medium containing either HΔP or the mutant proteins (MH, MHΔP). In contrast, none of the recombinant HtrA1-containing conditioned medium degraded acid-solubilized type I collagen (Fig. 6C).

DISCUSSION

This study demonstrates for the first time that HtrA1 plays a key role in the regulation of mineral deposition by osteoblasts. First, we have shown that HtrA1 is temporally expressed during osteoblast differentiation *in vitro*. Second, we demonstrated that mineralization is inhibited by marked overexpression of HtrA1 and is promoted by knocking down HtrA1 expression using siRNA. Furthermore, overexpression of HtrA1 down-regulated Cbfa1 and type I collagen mRNA at confluence and prevented the induction of mineralization by BMP-2. Third, by expressing a series of recombinant HtrA1 proteins, we demonstrate that the protease domain and the PDZ domain are essential for the inhibitory effect of HtrA1 on osteoblast mineralization. We also identified that HtrA1 cleaves decorin, fibronectin,

and matrix Gla protein, but not type I collagen, and that the PDZ domain in addition to the protease domain is required for the cleavage of MGP. We propose that HtrA1 may inhibit mineralization by multiple mechanisms that may not be mutually exclusive, including (i) modulating expression of specific osteoblast genes, (ii) altering BMP-2 and/or TGF-β activity, and/or (iii) cleaving specific matrix proteins that regulate differentiation or bone matrix formation either directly or indirectly.

The temporal pattern of HtrA1 expression demonstrated in this study is consistent with the *in vivo* expression reported by Tsuchiya *et al.* (6). We demonstrate increased HtrA1 expression prior to the appearance of mineralized nodules, and its subsequent down-regulation in fully mineralized cultures of 2T3 osteoblasts. *In vivo*, HtrA1 expression is associated with the appearance of the ossification center in mouse tissue, and HtrA1 is deposited in the matrix of embryonic and adult bone, with osteoid and newly

formed bone matrices appearing to accumulate larger amounts of HtrA1 than fully calcified bone (6). Together, these studies demonstrate that the expression of HtrA1 *in vitro* and *in vivo* is tightly regulated both temporally and spatially.

In this study, we demonstrate that overexpression of HtrA1 in osteoblasts or the addition of recombinant full-length HtrA1 to the culture medium markedly delays matrix mineralization, whereas mineralization is increased by knocking down HtrA1 expression. Overexpression of HtrA1 also prevented BMP-2-induced mineralization. Oka *et al.* (14) have previously shown that HtrA1 binds to and inhibits *in vitro* signaling mediated by several TGF-β family proteins, including BMP-2. This group reported that neither TGF-β, BMP-2, nor BMP-4 can be degraded by HtrA1 and that signals from the constitutively active BMP-4 receptor, caBMPR-1B, are not inhibited by this protease (14). Taken together, these results suggest that HtrA1 may inhibit BMP-2-induced mineralization of 2T3 cells by inhibiting the interaction of BMP-2 with its receptor, thereby preventing downstream signaling. This suggestion is consistent with the results of a previous study in which the inhibition of BMP signaling in 2T3 osteoblasts by overexpression of Smad ubiquitin regulatory factor 1 (Smurf1) also inhibited BMP-2-induced mineralized bone nodule formation *in vitro* (44).

Previous studies have shown that Cbfa1 (a master regulator of osteoblast differentiation) and type I collagen play key roles in the early stages of 2T3 osteoblast differentiation (22, 44–47). The expression of these genes is down-regulated in cells induced to overexpress Smurf1 or a truncated type IB BMP
HtrA1 Inhibits Mineral Deposition

<figure><img src="image_6.png" /></figure>

FIGURE 5. Recombinant HtrA1 decreases osteoblast mineralization, and the protease and PDZ domains are essential for this inhibition. In each experiment, concentrated recombinant proteins were added to 2T3 cultures from confluence (day 3), in equivalent amounts, i.e. equal total protein and equal amounts of recombinant HtrA1 proteins. Conditioned media from empty vector (EV)- transfected EBNA-293 cells were used to normalize total protein levels. HtrA1 proteins were added in excess (200-fold) of the highest levels present in mineralizing 2T3 cultures. A, 2T3 cells were treated with empty vector (panels i and iv), MutHtrA1 (panels ii and v), and HtrA1 (panels iii and vi) conditioned media (total protein = 10 µg) for 7 days (day 10). Alizarin red staining shows decreased mineral deposition in cells treated with HtrA1 relative to cells treated with MutHtrA1 and control EV-conditioned media.

receptor, resulting in reduced osteoblast differentiation and mineral deposition (44, 45). Interestingly, we demonstrate that HtrA1 overexpression also results in the down-regulation of these genes in confluent osteoblasts, suggesting that one of the mechanisms by which HtrA1 may inhibit mineralization is by modulating osteoblast gene expression, although further studies are required to confirm this hypothesis.

Further investigation of the functional role of HtrA1 highlighted the importance of both the protease and the PDZ domains for the inhibitory effect of recombinant HtrA1 on osteoblast mineralization. Previous studies have shown that the protease domain, but not the PDZ domain, is essential for the inhibition of TGF-β signaling by HtrA1 (14). In fact, proteins lacking the PDZ domain exhibited increased inhibitory activity on TGF-β signaling. Therefore, we investigated whether specific matrix proteins that are also known to regulate bone formation, mineralization, and/or growth factor availability were cleaved by HtrA1 and whether the protease and PDZ domains were essential for this activity.

We demonstrated that conditioned medium containing full-length recombinant HtrA1 cleaves decorin, fibronectin, and matrix Gla protein (MGP) but not type I collagen. Analogous to the treatment of 2T3 osteoblasts with recombinant HtrA1, anti-fibronectin antibodies inhibited the formation of mineralized nodules in osteoblasts in vitro (47). Furthermore, the binding of the fibronectin RGD sequence to cell-surface integrin receptors has been shown to be required for osteoblast differentiation (36). Recently, fibronectin was shown to be crucial for the regulation of TGF-β and LTBP-1 (latent transforming growth factor-binding protein) incorporation into the extracellular matrix of osteoblasts (35). Therefore, it is tempting to speculate that degradation of fibronectin by HtrA1 may disrupt matrix assembly and enhance TGF-β activity, thereby leading to an inhibition of mineral deposition.

There are conflicting reports on the role of decorin in osteoblast differentiation and mineralization. The majority of evidence suggests that decorin is an inhibitor of mineralization in bone and that its removal or fragmentation is necessary for mineralization to occur (48–50). However, the opposite effect has been demonstrated in the vasculature, where decorin has been shown to promote mineral deposition (51). Furthermore, the defective bone phenotype observed in biglycan and decorin double knock-out mice (52) highlights the importance of decorin in the formation of a mineralized bone matrix. Although the decorin knock-out alone does not exhibit any striking bone phenotype, the decrease in bone mass in the double knock-out is more severe than in the biglycan single knock-out. Bi et al. (53) reported that TGF-β was not properly sequenced in the extracellular matrix of these decorin/biglycan

Bar = 500 µm. B, mineral deposition was quantified by $ ^{45}Ca $ incorporation into the cell layer over 24 h. After 10 days, cultures treated with HtrA1 show a 1.8- and a 2-fold decrease in calcium deposition, relative to EV- and MutHtrA1-treated cells, respectively. Statistical analysis was performed using one-way analysis of variance and Tukey's post hoc test. *, $p < 0.001$ ($n = 3$). C, 2T3 cells were treated with EV (panels i and iv), HtrA1$\Delta$PDZ (panels ii and v), and HtrA1 (panels iii and vi) conditioned media (total protein = 20 µg) for 10 days (day 13). Alizarin red staining shows decreased mineral deposition in cells treated with HtrA1, compared with cells treated with HtrA1$\Delta$PDZ- or EV-conditioned media (bar = 500 µm).
<figure><img src="image_7.png" /></figure>

FIGURE 6. **HtrA1 cleaves specific matrix-associated proteins.** Recombinant HtrA1 proteins were incubated with candidate target proteins at 37 °C for 16 h. EV, empty vector; MH, MutHtrA1; H, HtrA1; MHΔP, MutHtrA1ΔPDZ; HΔP, HtrA1ΔPDZ; CM, conditioned media. A, human plasma fibronectin (Fn) (10 µg) was incubated with the indicated proteins and products, separated by SDS-PAGE, were analyzed by silver staining. Cleavage products of fibronectin were present following incubation with H and HΔP. B, Western blot analysis showing degradation of human recombinant decorin (4 µg) by H and HΔP (top panel). Decorin (0.2 µg) was digested with chondroitinase ABC, generating the doublet bands of the glycanated core protein (middle panel). H and HΔP cleaved this product further. Western blotting using an anti-FLAG antibody detected recombinant MGP migrating at ~15 kDa (bottom panel). Incubation of MGP with HtrA1 resulted in a cleavage product of ~12 kDa. C, rat tail type I collagen (10 µg) products were stained with Coomassie Blue. Collagen I migrates as two sets of doublet bands. The lower of the doublets corresponds to the α₁(I) and α₂(I) chains of collagen I and the higher doublet to the dimeric β(I) chains. Collagen I was not cleaved by any of the HtrA1 recombinant proteins or control conditioned media.

double knock-out mice, thereby altering the fate of bone marrow stromal cells, resulting in reduced bone formation and mineralization. It is possible that degradation of decorin by HtrA1 could release TGF-β bound within the matrix, making it available to interact with its receptor. Alternatively, HtrA1 may prevent decorin from sequestering TGF-β in the matrix and away from the cell-surface receptors. Either way this would result in decreased osteoblast mineralization.

MGP has been implicated in the regulation of both cell differentiation and mineralization, although the mechanism by

which it exerts these effects are still not fully understood (54–59). Several studies have shown that MGP functions as an inhibitor of mineralization in vitro and in vivo and that the Gla domains are required for this activity (42, 54, 60). However, the Gla domains of MGP also bind BMP-2 (56–58, 61–64), and it has been shown that the ability of MGP to regulate mineral deposition and osteogenic differentiation is dependent on the relative levels of MGP and BMP-2 present (57, 58). In this study we demonstrate that a small domain at the C terminus of MGP is cleaved by HtrA1, and this cleavage requires both the PDZ and protease domains of HtrA1. MGP has been shown to undergo processing at the C terminus, resulting in a 77–83-amino acid protein depending on species, although the protease(s) responsible for this cleavage have not been identified. Whether MGP is a physiological substrate for HtrA1 in vivo or whether cleavage of MGP by HtrA1 only occurs under pathological conditions is not known. As MGP binds to the matrix via amino acid residues 61–77 in its C-terminal domain (61, 65), it is tempting to speculate that HtrA1-mediated cleavage of MGP at the C terminus may enhance its ability to bind to the matrix, which, in turn, may inhibit BMP-2 signaling and mineralization, although further studies are required to test this hypothesis.

In conclusion, we demonstrate a novel function for HtrA1, as an inhibitor of matrix mineralization. HtrA1 may regulate mineralization either by modulating osteoblast gene expression, inhibiting growth factor signaling, and/or by cleaving specific matrix proteins. We suggest that the precise mechanism of action of HtrA1 may depend on the relative levels of individual growth factors and matrix proteins present and that perturbation in the levels of these molecules may result in aberrant mineral deposition. We further suggest that the de-regulation of HtrA1 expression in vivo may contribute to pathologies associated with aberrant mineral deposition.

*Acknowledgments*—We thank Drs. Keith Brennan and Pengbo Wang (University of Manchester, UK) for advice on siRNA experiments.

REFERENCES

1. Clausen, T., Southan, C., and Ehrmann, M. (2002) *Mol. Cell* **10**, 443–455

2. Zumbrunn, J., and Trueb, B. (1996) *FEBS Lett.* **398**, 187–192

3. Hu, S. I., Carozza, M., Klein, M., Nantermet, P., Luk, D., and Crowl, R. M. (1998) *J. Biol. Chem.* **273**, 34406–34412

4. Chien, J., Staub, J., Hu, S. I., Erickson-Johnson, M. R., Couch, F. J., Smith, D. I., Crowl, R. M., Kaufmann, S. H., and Shridhar, V. (2004) *Oncogene* **23**, 1636–1644

5. Baldi, A., De Luca, A., Morini, M., Battista, T., Felsani, A., Baldi, F., Catri-cala, C., Amantea, A., Noonan, D. M., Albini, A., Natali, P. G., Lombardi, D., and Paggi, M. G. (2002) *Oncogene* **21**, 6684–6688

6. Tsuchiya, A., Yano, M., Tocharus, J., Kojima, H., Fukumoto, M., Kawaichi, M., and Oka, C. (2005) *Bone (Elmsford)* **37**, 323–336

7. Grau, S., Richards, P. J., Kerr, B., Hughes, C., Caterson, B., Williams, A. S., Junker, U., Jones, S. A., Clausen, T., and Ehrmann, M. (2006) *J. Biol. Chem.* **281**, 6124–6129

8. Wu, J., Liu, W., Bemis, A., Wang, E., Qiu, Y., Flannery, C. R., and Yang, Z. (2007) *Arthritis Rheum.* **56**, 3675–36784

9. Grau, S., Baldi, A., Bussani, R., Tian, X., Stefanescu, R., Przybylski, M., Richards, P., Jones, S. A., Shridhar, V., Clausen, T., and Ehrmann, M. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102**, 6021–6026

10. Bakay, M., Zhao, P., Chen, J., and Hoffman, E. P. (2002) *Neuromuscul.*

<figure><img src="image_8.png" /></figure>
HtrA1 Inhibits Mineral Deposition

Disord. **12**, Suppl. 1, 125–141

11. Dewan, A., Liu, M., Hartman, S., Zhang, S. S., Liu, D. T., Zhao, C., Tam, P. O., Chan, W. M., Lam, D. S., Snyder, M., Barnstable, C., Pang, C. P., and Hoh, J. (2006) *Science* **314**, 989–992

12. Yang, Z., Camp, N. J., Sun, H., Tong, Z., Gibbs, D., Cameron, D. J., Chen, H., Zhao, Y., Pearson, E., Li, X., Chien, J., Dewan, A., Harmon, J., Bernstein, P. S., Shridhar, V., Zabriskie, N. A., Hoh, J., Howes, K., and Zhang, K. (2006) *Science* **314**, 992–993

13. Doherty, M., Boot-Handford, R. P., Grant, M. E., and Canfield, A. E. (1998) *Biochem. Soc. Trans.* **26**, S410

14. Oka, C., Tsujimoto, R., Kajikawa, M., Koshiba-Takeuchi, K., Ina, J., Yano, M., Tsuchiya, A., Ueta, Y., Soma, A., Kanda, H., Matsumoto, M., and Kawaichi, M. (2004) *Development* (Camb.) **131**, 1041–1053

15. Young, M. F. (2003) *Osteoporos. Int.* **14**, Suppl. 3, 35–42

16. Boskey, A. L., and Posner, A. S. (1984) *Orthop. Clin. North Am.* **15**, 597–612

17. Baylink, D. J., Finkelman, R. D., and Mohan, S. (1993) *J. Bone Miner. Res. 8*, Suppl. 2, 565–572

18. Bonewald, L. F., and Mundy, G. R. (1990) *Clin. Orthop. Relat. Res.* **250**, 261–276

19. Hoffmann, A., and Gross, G. (2001) *Crit. Rev. Eukaryotic Gene Expression* **11**, 23–45

20. Balemans, W., and Van Hul, W. (2002) *Dev. Biol.* **250**, 231–250

21. Tocharus, J., Tsuchiya, A., Kajikawa, M., Ueta, Y., Oka, C., and Kawaichi, M. (2004) *Dev. Growth Differ.* **46**, 257–274

22. Ghosh-Choudhury, N., Windle, J. J., Koop, B. A., Harris, M. A., Guerrero, D. L., Wozney, J. M., Mundy, G. R., and Harris, S. E. (1996) *Endocrinology* **137**, 331–339

23. Harris, S. E., Guo, D., Harris, M. A., Krishnaswamy, A., and Lichtler, A. (2003) *Front. Biosci.* **8**, S1249–S1265

24. Ghosh-Choudhury, N., Abboud, S. L., Nishimura, R., Celeste, A., Mahi-
mainathan, L., and Ghosh-Choudhury, G. (2002) *J. Biol. Chem.* **277*,
33361–33368

25. Yang, W., Lu, Y., Kalajzic, Guo, D., Harris, M. A., Gluhak-Heinrich, J., Kotha, S., Bonewald, L. F., Feng, J. Q., Rowe, D. W., Turner, C. H., Robling, A. G., and Harris, S. E. (2005) *J. Biol. Chem.* **280**, 20680–20690

26. Shukunami, C., Ishizeki, K., Atsumi, T., Ohta, Y., Suzuki, F., and Hiraki, Y. (1997) *J. Bone Miner. Res.* **12**, 1174–1188

27. Shioi, A., Nishizawa, Y., Jono, S., Koyama, H., Hosoi, M., and Morii, H. (1995) *Arterioscler. Thromb. Vasc. Biol.* **15**, 2003–2009

28. Kirton, J. P., Wilkinson, F. L., Canfield, A. E., and Alexander, M. Y. (2006) *Circ. Res.* **98**, 1264–1272

29. Van Craenenbroeck, K., Vanhoenacker, P., and Haegeman, G. (2000) *Eur. J. Biochem.* **267**, 5665–5678

30. Kohfeldt, E., Maurer, P., Vannahme, C., and Timpl, R. (1997) *FEBS Lett.* **414**, 557–561

31. Rock, M. J., Cain, S. A., Freeman, L. J., Morgan, A., Mellody, K., Marson, A., Shuttleworth, C. A., Weiss, A. S., and Kielty, C. M. (2004) *J. Biol. Chem.* **279**, 23748–23758

32. Murwantoko, Yano, M., Ueta, Y., Murasaki, A., Kanda, H., Oka, C., and Kawaichi, M. (2004) *Biochem. J.* **381**, 895–904

33. Velling, T., Risteli, J., Wennerberg, K., Mosher, D. F., and Johansson, S. (2002) *J. Biol. Chem.* **277**, 37377–37381

34. Pereira, M., Rybarczyk, B. J., Odr lin, T. M., Hocking, D. C., Sottile, J., and Simpson-Haidaris, P. J. (2002) *J. Cell Sci.* **115**, 609–617

35. Dallas, S. L., Sivakumar, P., Jones, C. J., Chen, Q., Peters, D. M., Mosher, D. F., Humphries, M. J., and Kielty, C. M. (2005) *J. Biol. Chem.* **280**, 18871–18880

36. Moursi, A. M., Globus, R. K., and Damsky, C. H. (1997) *J. Cell Sci.*

110, 2187–2196

37. Danielson, K. G., Baribault, H., Holmes, D. F., Graham, H., Kadler, K. E., and Iozzo, R. V. (1997) *J. Cell Biol.* **136**, 729–743

38. Hildebrand, A., Romaris, M., Rasmussen, L. M., Heinegard, D., Twardzik, D. R., Border, W. A., and Ruoslahti, E. (1994) *Biochem. J.* **302**, 527–534

39. Yamaguchi, Y., Mann, D. M., and Ruoslahti, E. (1990) *Nature* **346**, 281–284

40. Waddington, R. J., Roberts, H. C., Sugars, R. V., and Schonherr, E. (2003) *Eur. Cell Mater.* **6**, 12–21

41. Price, P. A., and Williamson, M. K. (1985) *J. Biol. Chem.* **260**, 14971–14975

42. Luo, G., Ducy, P., McKee, M. D., Pinero, G. J., Loyer, E., Behringer, R. R., and Karsenty, G. (1997) *Nature* **386**, 78–81

43. Landis, W. J. (1999) *Gravit. Space Biol. Bull.* **12**, 15–26

44. Zhao, M., Qiao, M., Harris, S. E., Oyajobi, B. O., Mundy, G. R., and Chen, D. (2004) *J. Biol. Chem.* **279**, 12854–12859

45. Chen, D., Ji, X., Harris, M. A., Feng, J. Q., Karsenty, G., Celeste, A. J., Rosen, V., Mundy, G. R., and Harris, S. E. (1998) *J. Cell Biol.* **142**, 295–305

46. Jikko, A., Harris, S. E., Chen, D., Mendrick, D. L., and Damsky, C. H. (1999) *J. Bone Miner. Res.* **14**, 1075–1083

47. Moursi, A. M., Damsky, C. H., Lull, J., Zimmerman, D., Doty, S. B., Aota, S., and Globus, R. K. (1996) *J. Cell Sci.* **109**, 1369–1380

48. Hoshi, K., Kemmotsu, S., Takeuchi, Y., Amizuka, N., and Ozawa, H. (1999) *J. Bone Miner. Res.* **14**, 273–280

49. Hoshi, K., Ejiri, S., and Ozawa, H. (2001) *J. Bone Miner. Res.* **16**, 289–298

50. Mochida, Y., Duarte, W. R., Tanzawa, H., Paschalis, E. P., and Yamauchi, M. (2003) *Biochem. Biophys. Res. Commun.* **305**, 6–9

51. Fischer, J. W., Steitz, S. A., Johnson, P. Y., Burke, A., Kolodgie, F., Virmani, R., Giachelli, C., and Wight, T. N. (2004) *Arterioscler. Thromb. Vasc. Biol.* **24**, 2391–2396

52. Corsi, A., Xu, T., Chen, X. D., Boyde, A., Liang, J., Mankani, M., Sommer, B., Iozzo, R. V., Eichstetter, I., Robey, P. G., Bianco, P., and Young, M. F. (2002) *J. Bone Miner. Res.* **17**, 1180–1189

53. Bi, Y., Stuelten, C. H., Kilts, T., Wadhwa, S., Iozzo, R. V., Robey, P. G., Chen, X. D., and Young, M. F. (2005) *J. Biol. Chem.* **280**, 30481–30489

54. Newman, B., Gigout, L. I., Sudre, L., Grant, M. E., and Wallis, G. A. (2001) *J. Cell Biol.* **154**, 659–666

55. Yagami, K., Suh, J. Y., Enomoto-Iwamoto, M., Koyama, E., Abrams, W. R., Shapiro, I. M., Pacifici, M., and Iwamoto, M. (1999) *J. Cell Biol.* **147**, 1097–1108

56. Bostrom, K., Tsao, D., Shen, S., Wang, Y., and Demer, L. L. (2001) *J. Biol. Chem.* **276**, 14044–14052

57. Zebboudj, A. F., Imura, M., and Bostrom, K. (2002) *J. Biol. Chem.* **277**, 4388–4394

58. Zebboudj, A. F., Shin, V., and Bostrom, K. (2003) *J. Cell. Biochem.* **90**, 756–765

59. Canfield, A. E., Doherty, M. J., Kelly, V., Newman, B., Farrington, C., Grant, M. E., and Boot-Handford, R. P. (2000) *FEBS Lett.* **487**, 267–271

60. Murshed, M., Schinke, T., McKee, M. D., and Karsenty, G. (2004) *J. Cell Biol.* **165**, 625–630

61. Wajih, N., Borras, T., Xue, W., Hutson, S. M., and Wallin, R. (2004) *J. Biol. Chem.* **279**, 43052–43060

62. Price, P. A., Nguyen, T. M., and Williamson, M. K. (2003) *J. Biol. Chem.* **278**, 22153–22160

63. Wallin, R., Cain, D., Hutson, S. M., Sane, D. C., and Loeser, R. (2000) *Thromb. Haemostasis* **84**, 1039–1044

64. Sweatt, A., Sane, D. C., Hutson, S. M., and Wallin, R. (2003) *J. Thromb. Haemostasis* **1**, 178–185

65. Nishimoto, S. K., and Nishimoto, M. (2005) *Matrix Biol.* **24**, 353–361